Biologic ‘dampens symptoms’ in new-onset myasthenia gravis
Need for rescue treatment reduced with add-on rituximab compared with placebo
A single infusion of rituximab in patients with recent-onset generalised myasthenia gravis greatly reduces the need for rescue treatment or hospitalisation compared with placebo, new research shows.
Swedish neurologists say the biologic is also associated with minimal disease manifestations despite low corticosteroid doses in the short to medium term.
